Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Chronic hepatitis C infection in children
E. Broide
*
,
N. A. Kimchi
,
E. Scapa
*
Corresponding author for this work
Clinical Departments
Internal Medicine
Assaf Harofeh Medical Center
Tel Aviv University
Research output
:
Contribution to journal
›
Article
›
peer-review
6
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Chronic hepatitis C infection in children'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Chronic Hepatitis C Infection
100%
Infections in children
100%
Hepatitis C Virus Infection
100%
Hepatitis C Virus
75%
Major Risk Factors
25%
Randomized Controlled Trial
25%
Disease Course
25%
Risk Factors
25%
Natural History
25%
Response to Treatment
25%
Pediatric Population
25%
Infected children
25%
Geographical Distribution
25%
Chronic Hepatitis
25%
Progression Rate
25%
Ribavirin
25%
Combination Treatment
25%
Natural Response
25%
Efficient Transmission
25%
Advanced Liver Disease
25%
Blood Products
25%
Ropeginterferon alfa-2b
25%
Mild Course
25%
Maternal-infant Transmission
25%
Percutaneous Exposure
25%
Medicine and Dentistry
Infection
100%
Chronic Hepatitis C
100%
Hepatitis C
100%
Hepatitis C Virus
75%
Randomized Controlled Trial
25%
Liver Disease
25%
Pediatrics
25%
Geographic Distribution
25%
Ribavirin
25%
Blood Product
25%
Chronic Hepatitis
25%
Peginterferon Alpha2b
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Chronic Hepatitis C
100%
Hepatitis C
100%
Hepatitis C Virus
75%
Randomized Controlled Trial
25%
Chronic Hepatitis
25%
Geographic Distribution
25%
Liver Disease
25%
Ribavirin
25%
Peginterferon Alpha2b
25%
Diseases
25%
Immunology and Microbiology
Hepatitis C
100%
Hepatitis C Virus
60%
Geographic Distribution
20%
Blood Product
20%
Peginterferon Alfa-2b
20%
Ribavirin
20%